PCI Biotech Holding ASA (OSL:PCIB) Other Operating Expense : kr-6.74 Mil (TTM As of Dec. 2024)

View and export this data going back to 2008. Start your Free Trial

What is PCI Biotech Holding ASA Other Operating Expense?

PCI Biotech Holding ASA's Other Operating Expense for the six months ended in Dec. 2024 was kr-3.31 Mil. Its Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2024 was kr-6.74 Mil.

PCI Biotech Holding ASA's quarterly Other Operating Expense declined from Dec. 2023 (kr-2.57 Mil) to Jun. 2024 (kr-3.43 Mil) but then increased from Jun. 2024 (kr-3.43 Mil) to Dec. 2024 (kr-3.31 Mil).

PCI Biotech Holding ASA's annual Other Operating Expense increased from Dec. 2022 (kr-4.75 Mil) to Dec. 2023 (kr-2.99 Mil) but then declined from Dec. 2023 (kr-2.99 Mil) to Dec. 2024 (kr-6.74 Mil).

PCI Biotech Holding ASA Other Operating Expense Historical Data

The historical data trend for PCI Biotech Holding ASA's Other Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

PCI Biotech Holding ASA Other Operating Expense Chart

PCI Biotech Holding ASA Annual Data

Trend

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Other Operating Expense

Get a 7-Day Free Trial

-7.37

-6.27

-4.75

-2.99

-6.74

PCI Biotech Holding ASA Semi-Annual Data
	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24	Dec24
Other Operating Expense	Get a 7-Day Free Trial															-2.38	-0.42	-2.57	-3.43	-3.31

PCI Biotech Holding ASA Other Operating Expense Calculation

GuruFocus uses a standardized financial statement format for all companies. For non-financial companies, GuruFocus lists Selling, General, & Admin. Expense, , Research & Development, and Other Operating Expense under the "Total Operating Expense" section.

Other Operating Expense sometimes includes:
Restructuring, and merger
Acquisition related and other
Litigation settlement charge
Other (too numerous to list)

Some companies can and do choose to report each of these items separately. Yet, there are a variety of Other Operating Expense which are simply too numerous to list.

Other Operating Expense for the trailing twelve months (TTM) ended in Dec. 2024 adds up the semi-annually data reported by the company within the most recent 12 months, which was kr-6.74 Mil.

PCI Biotech Holding ASA Other Operating Expense Related Terms

Thank you for viewing the detailed overview of PCI Biotech Holding ASA's Other Operating Expense provided by GuruFocus.com. Please click on the following links to see related term pages.

PCI Biotech Holding ASA Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » PCI Biotech Holding ASA (OSL:PCIB) » Definitions » Other Operating Expense

Comparable Companies

Traded in Other Exchanges

0JGL:UK 4QG:Germany

Address

Ullernchausseen 64, Oslo, NOR, N-0379

Website

https://www.pcibiotech.com

PCI Biotech Holding ASA is a biopharmaceutical company focused on developing and commercializing cancer therapies using its photochemical internalization (PCI) technology platform. The PCI technology utilizes light to trigger the release of compounds from within cellular compartments. The company applies PCI to three different approaches for cancer treatment: fimaCHEM: Enhancing chemotherapeutic drugs for localized cancer treatment. fimaVACC: Inducing T-cell responses for therapeutic cancer vaccination. fimaNAc: Delivering nucleic acid therapeutics. The key product candidate is fimaporfin (Amphinex), a photosensitizer that can unlock intracellular compartments where active compounds are trapped. The company's sole operating segment is research and development.

PCI Biotech Holding ASA Headlines

No Headlines